NeOnc Technologies reported third quarter 2026 financial results characterized by a 49% reduction in net loss and the achievement of primary endpoints in its lead clinical program. The company strengthened its balance sheet through a $15 million capital raise and eliminated potential dilution by redeeming its Series A preferred stock.
Key Highlights
- The Phase 2a trial of intranasal NEO100 met its primary endpoint with a 48.9% six-month progression-free survival rate, significantly exceeding the 20% standard-of-care benchmark.
- Net loss narrowed to $4.4 million from $8.6 million in the prior-year period, driven by lower non-cash stock-based compensation and a reduction in general and administrative expenses to $0.6 million.
- Cash and equivalents increased to $6.2 million as of September 30, 2026, following a $15 million registered direct offering and the subsequent $5.8 million cash redemption of Series A Convertible Preferred Stock.